$NAMS
NewAmsterdam Pharma Co N.V.

2024 Q1 Form 10-K Financial Statement

#000095017024021668 Filed on February 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $1.401M $14.09M
YoY Change -83.76% -85.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.45M $37.63M
YoY Change 79.27% 69.29%
% of Gross Profit
Research & Development $42.43M $159.4M
YoY Change 4.97% 93.88%
% of Gross Profit
Depreciation & Amortization $15.00K $49.00K
YoY Change 66.67% -31.94%
% of Gross Profit
Operating Expenses $56.88M $197.1M
YoY Change 17.33% 88.64%
Operating Profit -$55.48M -$183.0M
YoY Change 39.22% 5043.86%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$93.77M -$176.9M
YoY Change 123.16% 126.66%
Income Tax $27.00K
% Of Pretax Income
Net Earnings -$93.77M -$176.9M
YoY Change 123.16% 126.69%
Net Earnings / Revenue -6692.86% -1255.76%
Basic Earnings Per Share -$1.06 -$2.15
Diluted Earnings Per Share -$1.06 -$2.15
COMMON SHARES
Basic Shares Outstanding 89.27M 82.16M
Diluted Shares Outstanding 88.38M 82.16M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $481.1M $340.5M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables $3.985M $875.0K
Total Short-Term Assets $487.8M $346.8M
YoY Change -22.61%
LONG-TERM ASSETS
Property, Plant & Equipment $101.0K $46.00K
YoY Change -68.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $641.0K $306.0K
YoY Change -99.63%
TOTAL ASSETS
Total Short-Term Assets $487.8M $346.8M
Total Long-Term Assets $641.0K $306.0K
Total Assets $488.5M $347.1M
YoY Change -34.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.536M $16.92M
YoY Change -8.54%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $59.73M $49.90M
YoY Change 40.71%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $59.73M $49.90M
Total Long-Term Liabilities
Total Liabilities $76.66M $58.70M
YoY Change 24.74%
SHAREHOLDERS EQUITY
Retained Earnings -$410.7M -$317.0M
YoY Change 126.37%
Common Stock $818.1M $600.9M
YoY Change 6.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $411.8M $288.4M
YoY Change
Total Liabilities & Shareholders Equity $488.5M $347.1M
YoY Change -34.71%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$93.77M -$176.9M
YoY Change 123.16% 126.69%
Depreciation, Depletion And Amortization $15.00K $49.00K
YoY Change 66.67% -31.94%
Cash From Operating Activities -$54.60M -$141.2M
YoY Change 71.36% -1871.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$385.0K -$24.00K
YoY Change 5400.0% -103.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 198.2M 8.912M
YoY Change 8185.12% -97.62%
NET CHANGE
Cash From Operating Activities -54.60M -141.2M
Cash From Investing Activities -385.0K -24.00K
Cash From Financing Activities 198.2M 8.912M
Net Change In Cash 143.2M -132.3M
YoY Change -585.76% -134.47%
FREE CASH FLOW
Cash From Operating Activities -$54.60M -$141.2M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001936258
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-41562
CY2023 dei Entity Registrant Name
EntityRegistrantName
NewAmsterdam Pharma Company N.V.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
Gooimeer 2-35
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
1411 DC
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Naarden
CY2023 dei Entity Address Country
EntityAddressCountry
NL
CY2023 dei City Area Code
CityAreaCode
+31
CY2023 dei Local Phone Number
LocalPhoneNumber
(0) 35 206 2971
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
false
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
true
CY2023 dei Document Fin Stmt Restatement Recovery Analysis Flag
DocumentFinStmtRestatementRecoveryAnalysisFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
577433308
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89266673
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
1243
CY2023 dei Auditor Name
AuditorName
Deloitte Accountants B.V
CY2023 dei Auditor Location
AuditorLocation
Eindhoven, The Netherlands
CY2023Q4 us-gaap Cash
Cash
340450000
CY2022Q4 us-gaap Cash
Cash
467728000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6341000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10251000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
346791000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
477979000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
120000
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
170000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
208000
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
35000
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
156000
CY2023Q4 us-gaap Assets
Assets
347097000
CY2022Q4 us-gaap Assets
Assets
478497000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16923000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11853000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11398000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
6117000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8942000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
13874000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
60000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
66000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
12574000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4147000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49897000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36057000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1019000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4792000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
60000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
7788000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
7522000
CY2023Q4 us-gaap Liabilities
Liabilities
58704000
CY2022Q4 us-gaap Liabilities
Liabilities
48431000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82469768
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82469768
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81559780
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81559780
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10173000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10055000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
590771000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
555625000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316973000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140036000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4422000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4422000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
288393000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
430066000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
347097000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
478497000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14090000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102694000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159424000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86744000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28974000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37633000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19507000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6003000
CY2023 us-gaap Operating Expenses
OperatingExpenses
197057000
CY2022 us-gaap Operating Expenses
OperatingExpenses
106251000
CY2021 us-gaap Operating Expenses
OperatingExpenses
34977000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-182967000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-3557000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-34977000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
11283000
CY2022 us-gaap Interest Expense
InterestExpense
287000
CY2021 us-gaap Interest Expense
InterestExpense
411000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-883000
CY2023 nams Change In Fair Value Of Earnout And Warrants
ChangeInFairValueOfEarnoutAndWarrants
10284000
CY2022 nams Change In Fair Value Of Earnout And Warrants
ChangeInFairValueOfEarnoutAndWarrants
1041000
CY2022 nams Change In Fair Value Of Profit Rights
ChangeInFairValueOfProfitRights
12390000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5000
CY2023 nams Noncash Rent Expense
NoncashRentExpense
6000
CY2022 nams Noncash Rent Expense
NoncashRentExpense
10000
CY2021 nams Change In Fair Value Of Profit Rights
ChangeInFairValueOfProfitRights
20613000
CY2022 nams Change In Fair Value Of Tranche Rights
ChangeInFairValueOfTrancheRights
4388000
CY2021 nams Change In Fair Value Of Tranche Rights
ChangeInFairValueOfTrancheRights
13393000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5058000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9747000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1706000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-176910000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22634000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41785000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-176937000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-22634000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41785000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
11126000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
286000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-176937000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11508000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41499000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.15
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.15
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.81
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.81
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-73035000
CY2021 nams Temporary Equity Shares Conversion Of Convertible Debt
TemporaryEquitySharesConversionOfConvertibleDebt
1111115
CY2021 nams Temporary Equity Values Conversion Of Convertible Debt
TemporaryEquityValuesConversionOfConvertibleDebt
12953000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
718000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41499000
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
6039728
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
84541000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-113816000
CY2022 nams Adjustments To Additional Paid In Capital Repayment Of Loan
AdjustmentsToAdditionalPaidInCapitalRepaymentOfLoan
747000
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
-5794000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4327000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11508000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
430066000
CY2023 nams Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
10213000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
290000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24761000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-176937000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
288393000
CY2023 us-gaap Profit Loss
ProfitLoss
-176937000
CY2022 us-gaap Profit Loss
ProfitLoss
-22634000
CY2021 us-gaap Profit Loss
ProfitLoss
-41785000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
49000
CY2021 nams Noncash Rent Expense
NoncashRentExpense
2000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
155000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-883000
CY2022 nams Change In Fair Value Tranche Rights
ChangeInFairValueTrancheRights
-4388000
CY2021 nams Change In Fair Value Tranche Rights
ChangeInFairValueTrancheRights
-13393000
CY2022 nams Change In Fair Value Of Inprocess Research And Development
ChangeInFairValueOfInprocessResearchAndDevelopment
12390000
CY2021 nams Change In Fair Value Of Inprocess Research And Development
ChangeInFairValueOfInprocessResearchAndDevelopment
20613000
CY2023 nams Change In Fair Value Of Derivative Earnout And Warrants
ChangeInFairValueOfDerivativeEarnoutAndWarrants
10284000
CY2022 nams Change In Fair Value Of Derivative Earnout And Warrants
ChangeInFairValueOfDerivativeEarnoutAndWarrants
1041000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5058000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9747000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1706000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
24572000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4117000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1244000
CY2023 nams Increase Decrease In Prepayments And Other Receivables
IncreaseDecreaseInPrepaymentsAndOtherReceivables
-4031000
CY2022 nams Increase Decrease In Prepayments And Other Receivables
IncreaseDecreaseInPrepaymentsAndOtherReceivables
4185000
CY2021 nams Increase Decrease In Prepayments And Other Receivables
IncreaseDecreaseInPrepaymentsAndOtherReceivables
5232000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5070000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4809000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6558000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5470000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-8679000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3144000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8705000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
18428000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-141218000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10665000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29512000
CY2023 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
24000
CY2022 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
221000
CY2021 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
24000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-221000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000
CY2022 nams Transaction Costs On Issue Of Shares
TransactionCostsOnIssueOfShares
5794000
CY2022 nams Proceeds From Payment Of Shareholder Loan
ProceedsFromPaymentOfShareholderLoan
747000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8622000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
290000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8912000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
391905000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
84704000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-132330000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
402349000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
55168000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5052000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5248000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4683000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
467728000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60131000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9646000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
340450000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
467728000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60131000
CY2022 nams Derivative Earnout Obligation Recognized Related To Business Combination
DerivativeEarnoutObligationRecognizedRelatedToBusinessCombination
-6815000
CY2022 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
4006000
CY2022 nams Contribution Of Interest In Newamsterdam Pharma Holding Bv By Paricipating Shareholders
ContributionOfInterestInNewamsterdamPharmaHoldingBVByParicipatingShareholders
-179231000
CY2022 nams Issuance Of Ordinary Shares To Participating Shareholders
IssuanceOfOrdinarySharesToParticipatingShareholders
179231000
CY2022 nams Issuance Of Ordinary Shares Pursuant To The Profit Right Agreement
IssuanceOfOrdinarySharesPursuantToTheProfitRightAgreement
85439000
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
12953000
CY2021 nams Recognition Of Rou Asset
RecognitionOfRouAsset
196000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
277000
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
27000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-317000000
CY2023Q4 us-gaap Cash
Cash
340500000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related to the Company’s revenue recognition, accrual of research and development expenses, valuation of stock option awards and valuation of derivative instruments. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivative Earnout Liability</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for the Earnout Shares (as defined below) allocated to Participating Shareholders (as defined below) in accordance with the guidance contained in ASC 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASC 815-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging—Contracts in Entity's Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, under which the Earnout Shares allocated to Participating Shareholders do not meet the criteria for equity treatment and must be recorded as liabilities carried at fair value. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as (expense)/income in the consolidated statements of operations and comprehensive loss. The liability is valued utilizing the Black-Scholes model, taking into account the probability of achieving the applicable milestone. The valuation of the Earnout Shares allocated to Participating Shareholders is considered to be a Level 3 fair value measurement.</span></p>
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
160000000
CY2023 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
greater than 50% likelihood
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36258312
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023 us-gaap Revenue Performance Obligation Description Of Good Or Service
RevenuePerformanceObligationDescriptionOfGoodOrService
As such, two performance obligations for the Menarini License were identified at contract inception, comprising a license to use the Company’s intellectual property
CY2023Q4 nams Number Of Performance Obligations
NumberOfPerformanceObligations
2
CY2022Q3 nams Upfront Payment Received To Initial Transaction Price
UpfrontPaymentReceivedToInitialTransactionPrice
120900000
CY2022Q4 nams Allocation To License Performance Obligation
AllocationToLicensePerformanceObligation
98600000
CY2023 nams Contingent Payment
ContingentPayment
863000000
CY2023 nams License Revenue Attributed From License Performance Obligations
LicenseRevenueAttributedFromLicensePerformanceObligations
5385000
CY2022 nams License Revenue Attributed From License Performance Obligations
LicenseRevenueAttributedFromLicensePerformanceObligations
98613000
CY2023 nams License Revenue Attributed From R And D Performance Obligations
LicenseRevenueAttributedFromRAndDPerformanceObligations
8705000
CY2022 nams License Revenue Attributed From R And D Performance Obligations
LicenseRevenueAttributedFromRAndDPerformanceObligations
4081000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14090000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102694000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
18666000
CY2022 nams Addition Of Deferred Revenue
AdditionOfDeferredRevenue
22332000
CY2023 nams Deferred Revenue Recognized
DeferredRevenueRecognized
8705000
CY2022 nams Deferred Revenue Recognized
DeferredRevenueRecognized
4081000
CY2022 nams Deferred Revenue Effect Of Currency Translation
DeferredRevenueEffectOfCurrencyTranslation
415000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
9961000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
18666000
CY2023Q4 nams Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
2337000
CY2022Q4 nams Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
5771000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2123000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2410000
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1006000
CY2022Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
2070000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
875000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6341000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10251000
CY2023Q4 nams Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
5945000
CY2022Q4 nams Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
1137000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3384000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1998000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2069000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2982000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11398000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
6117000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
each holder of Ordinary Shares is entitled to one vote per share on all matters to be voted on by shareholders
CY2023 nams Common Stock Number Of Vote Per Share
CommonStockNumberOfVotePerShare
1
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11146861
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.71
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6829024
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.63
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
160247
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.81
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2032129
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.51
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15783509
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.98
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
50796000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5230531
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.08
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
37101000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.7
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.32
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.11
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1700000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.041
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.039
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.006
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.381
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.388
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.429
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24572000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4178000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1212000
CY2023 nams Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Unrecognized Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsUnrecognizedCompensationCost
25200000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y4M24D
CY2021Q3 nams Underlying Ordinary Shares1
UnderlyingOrdinaryShares1
838806
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0013
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
608779
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
608779
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
519999
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
367804
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-107555000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-604000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-13542000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-69355000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-22030000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-28243000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-176910000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22634000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41785000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
27000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
27000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.258
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0294
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0156
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0071
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0003
CY2022 us-gaap Effective Income Tax Rate Reconciliation Fdii Percent
EffectiveIncomeTaxRateReconciliationFdiiPercent
0.0024
CY2023 nams Effective Income Tax Rate Reconciliation Warrants
EffectiveIncomeTaxRateReconciliationWarrants
-0.015
CY2022 nams Effective Income Tax Rate Reconciliation Warrants
EffectiveIncomeTaxRateReconciliationWarrants
-0.0119
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0531
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0073
CY2022 nams Effective Income Tax Rate Reconciliation Transaction Costs
EffectiveIncomeTaxRateReconciliationTransactionCosts
0.2459
CY2022 nams Effective Income Tax Rate Reconciliation Share Listing Expense
EffectiveIncomeTaxRateReconciliationShareListingExpense
0.0696
CY2021 nams Effective Income Tax Rate Reconciliation Share Listing Expense
EffectiveIncomeTaxRateReconciliationShareListingExpense
0.0763
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.274
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.573
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3186
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0033
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0001
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0002
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 nams Deferred Tax Assets Amortization And Depreciation
DeferredTaxAssetsAmortizationAndDepreciation
21176000
CY2022Q4 nams Deferred Tax Assets Amortization And Depreciation
DeferredTaxAssetsAmortizationAndDepreciation
371000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
509000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
167000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
75686000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
57766000
CY2023Q4 nams Deferred Tax Assets Lease Liability Arrangements
DeferredTaxAssetsLeaseLiabilityArrangements
13000
CY2022Q4 nams Deferred Tax Assets Lease Liability Arrangements
DeferredTaxAssetsLeaseLiabilityArrangements
29000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
22884000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
22884000
CY2023Q4 nams Deferred Tax Assets Tax Credit Federal
DeferredTaxAssetsTaxCreditFederal
6904000
CY2022Q4 nams Deferred Tax Assets Tax Credit Federal
DeferredTaxAssetsTaxCreditFederal
167000
CY2023Q4 nams Deferred Tax Assets Tax Credit Massachusetts
DeferredTaxAssetsTaxCreditMassachusetts
2685000
CY2022Q4 nams Deferred Tax Assets Tax Credit Massachusetts
DeferredTaxAssetsTaxCreditMassachusetts
23000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
129857000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
81407000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
129845000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
81380000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
12000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
27000
CY2023Q4 nams Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
12000
CY2022Q4 nams Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
27000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
129800000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
81400000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 nams Shares Exchanging Ratio
SharesExchangingRatio
0.0213
CY2023 nams Shares Exchanging Ratio
SharesExchangingRatio
0.0213
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-176937000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-22634000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41785000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82161956
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82161956
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18966235
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18966235
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10978874
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10978874
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.15
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.15
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.81
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.81
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19800730
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15913861
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4185360
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2023 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.50
CY2023 nams Defined Contribution Plan Employer Matching Additional Contribution Upon Employee Percent
DefinedContributionPlanEmployerMatchingAdditionalContributionUponEmployeePercent
0.02
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
120000
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
70000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
40000
CY2023Q4 nams Estimated Maximum Cancellation Fees
EstimatedMaximumCancellationFees
15700000

Files In Submission

Name View Source Status
0000950170-24-021668-index-headers.html Edgar Link pending
0000950170-24-021668-index.html Edgar Link pending
0000950170-24-021668.txt Edgar Link pending
0000950170-24-021668-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img106941042_0.jpg Edgar Link pending
img106941042_1.jpg Edgar Link pending
img106941042_10.jpg Edgar Link pending
img106941042_11.jpg Edgar Link pending
img106941042_12.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img106941042_13.jpg Edgar Link pending
img106941042_14.jpg Edgar Link pending
img106941042_15.jpg Edgar Link pending
img106941042_16.jpg Edgar Link pending
img106941042_2.jpg Edgar Link pending
img106941042_3.jpg Edgar Link pending
img106941042_4.jpg Edgar Link pending
img106941042_5.jpg Edgar Link pending
img106941042_6.jpg Edgar Link pending
img106941042_7.jpg Edgar Link pending
img106941042_8.jpg Edgar Link pending
img106941042_9.jpg Edgar Link pending
img194721301_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nams-20231231.htm Edgar Link pending
nams-20231231.xsd Edgar Link pending
nams-ex10_10.htm Edgar Link pending
nams-ex10_4.htm Edgar Link pending
nams-ex10_7.htm Edgar Link pending
nams-ex10_8.htm Edgar Link pending
nams-ex10_9.htm Edgar Link pending
nams-ex23_1.htm Edgar Link pending
nams-ex31_1.htm Edgar Link pending
nams-ex31_2.htm Edgar Link pending
nams-ex32_1.htm Edgar Link pending
nams-ex32_2.htm Edgar Link pending
nams-ex4_4.htm Edgar Link pending
nams-ex97_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nams-20231231_htm.xml Edgar Link completed